Submissions for variant NM_000546.6(TP53):c.892G>A (p.Glu298Lys)

dbSNP: rs201744589

Total submissions: 12

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
ClinGen TP53 Variant Curation Expert Panel, ClinGen	RCV000206802	SCV001142530	benign	Li-Fraumeni syndrome	2024-08-05	reviewed by expert panel	curation	The NM_000546.6 :c.892G>A variant in TP53 is a missense variant predicted to cause substitution of glutamic acid by lysine at amino acid 298 (p.Gly298Lys). This variant has been observed in 4-7 heterozygous unrelated females from the same data source with no personal history of cancer prior to age 60 years and no personal history of sarcoma at any age (BS2_Moderate; SCV000184859, SCV000260657). In vitro assays performed in yeast and/or human cell lines showed functional transactivation and retained growth suppression activity indicating that this variant does not impact protein function (BS3; PMIDs: 12826609, 29979965, 30224644). Computational predictor scores (BayesDel = -0.199; Align GVGD Class 0) are below the recommended thresholds (BayesDel ≤ -0.008 and an Align GVGD Class ≤ 55), evidence that does not predict a damaging effect on TP53 via protein change. SpliceAI predicts that the variant has no impact on splicing (BP4_Moderate). In summary, this variant meets the criteria to be classified as Benign for Li Fraumeni Syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: BS2_Moderate, BS3, BP4_Moderate. (Bayesian Points: -8; VCEP specifications version 2.0; 7/24/2024)
Ambry Genetics	RCV000130033	SCV000184859	likely benign	Hereditary cancer-predisposing syndrome	2018-04-25	criteria provided, single submitter	clinical testing	This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Labcorp Genetics (formerly Invitae), Labcorp	RCV000206802	SCV000260657	likely benign	Li-Fraumeni syndrome	2024-01-26	criteria provided, single submitter	clinical testing
Counsyl	RCV000411322	SCV000488500	uncertain significance	Li-Fraumeni syndrome 1	2016-04-14	criteria provided, single submitter	clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV000986055	SCV001134879	uncertain significance	not provided	2019-03-04	criteria provided, single submitter	clinical testing
Color Diagnostics, LLC DBA Color Health	RCV000130033	SCV001342499	uncertain significance	Hereditary cancer-predisposing syndrome	2022-12-15	criteria provided, single submitter	clinical testing	This missense variant replaces glutamic acid with lysine at codon 298 of the TP53 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Experimental studies have shown this variant to be functional in transcriptional transactivation and cell growth suppression assays (PMID: 12826609, 30224644). This variant has been reported in individuals affected with gastric cancer and acute lymphocytic leukemia in the literature (PMID: 21747090, 31949278). In a large international case-control study, this variant was reported in 1/60465 breast cancer cases and 2/53459 controls (OR=0.442, 95%CI 0.04 to 4.876, p-value=0.603; PMID: 33471991). This variant has been identified in 3/251492 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
CeGaT Center for Human Genetics Tuebingen	RCV000986055	SCV002498235	likely benign	not provided	2022-01-01	criteria provided, single submitter	clinical testing
Myriad Genetics, Inc.	RCV000411322	SCV004017845	uncertain significance	Li-Fraumeni syndrome 1	2023-04-11	criteria provided, single submitter	clinical testing	This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV003993819	SCV004813658	uncertain significance	not specified	2024-02-05	criteria provided, single submitter	clinical testing	Variant summary: TP53 c.892G>A (p.Glu298Lys) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 251492 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.892G>A has been reported in the literature in individuals affected with breast cancer, childhood acute lymphoblastic leukemia, or osteosarcoma (e.g. Mirabello_2015, Qian_2018, Sheng_2020). These reports do not provide unequivocal conclusions about association of the variant with Li-Fraumeni Syndrome. The variant has been reported to be functional based on overall transcription activity on eight different promoters as measured in yeast assays (Kato_2003) and results of growth suppression assays indicated no loss of function or dominant negative effect of this variant (Giacomelli_2018). ClinVar contains an entry for this variant (Variation ID: 141483). Based on the evidence outlined above, the variant was classified as uncertain significance.
All of Us Research Program, National Institutes of Health	RCV000206802	SCV004823752	uncertain significance	Li-Fraumeni syndrome	2024-01-11	criteria provided, single submitter	clinical testing	This missense variant replaces glutamic acid with lysine at codon 298 of the TP53 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Experimental studies have shown this variant to be functional in transcriptional transactivation and cell growth suppression assays (PMID: 12826609, 30224644). This variant has been reported in individuals affected with gastric cancer and acute lymphocytic leukemia in the literature (PMID: 21747090, 31949278). In a large international case-control study, this variant was reported in 1/60465 cases breast cancer cases and 2/53459 controls (OR=0.442, 95%CI 0.04 to 4.876, p-value=0.603; PMID: 33471991). This variant has been identified in 3/251492 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Department of Pathology and Laboratory Medicine, Sinai Health System	RCV001355227	SCV001550050	uncertain significance	Malignant tumor of breast		no assertion criteria provided	clinical testing	The TP53 p.Glu298Lys variant has been identified in 2 of 530 proband chromosomes (frequency: 0.004) of individuals affected with leukemia (Hof 2011). The variant was also identified in the following databases: dbSNP (ID: rs201744589) as “With Uncertain significance allele”, ClinVar (reported 3x as likely benign and uncertain significance by Ambry Genetics, Invitae and Counsyl), Cosmic (2x recurrence, endometrium, haematopoietic, Sinonasal and nasal cavity tissues, as carcinoma and lymphoid neoplasm) and IARC TP53 Database (7x somatic, 1x germline). The variant was not identified in Clinvitae, LOVD 3.0, UMD TP53 Mutation Database, and Database of germline p53 mutations. The variant was identified in control databases in 3 of 246268 chromosomes at a frequency of 0.000012 (Genome Aggregation Database Feb 27, 2017). It was observed in the following populations: Latino in 2 of 33582 chromosomes (freq: 0.00006), and South Asian in 1 of 30782 chromosomes (freq: 0.00003). It was not observed in the African, Other, European Non-Finnish, Ashkenazi Jewish, East Asian, and Finnish populations. The p.Glu298Lys residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.
Department of Pathology and Laboratory Medicine, Sinai Health System	RCV001355706	SCV001550662	uncertain significance	Carcinoma of colon		no assertion criteria provided	clinical testing	The TP53 p.Glu298Lys variant has been identified in 2 of 530 proband chromosomes (frequency: 0.004) of individuals affected with leukemia (Hof 2011). The variant was also identified in the following databases: dbSNP (ID: rs201744589) as “With Uncertain significance allele”, ClinVar (reported 3x as likely benign and uncertain significance by Ambry Genetics, Invitae and Counsyl), Cosmic (2x recurrence, endometrium, haematopoietic, Sinonasal and nasal cavity tissues, as carcinoma and lymphoid neoplasm) and IARC TP53 Database (7x somatic, 1x germline). The variant was not identified in Clinvitae, LOVD 3.0, UMD TP53 Mutation Database, and Database of germline p53 mutations. The variant was identified in control databases in 3 of 246268 chromosomes at a frequency of 0.000012 (Genome Aggregation Database Feb 27, 2017). It was observed in the following populations: Latino in 2 of 33582 chromosomes (freq: 0.00006), and South Asian in 1 of 30782 chromosomes (freq: 0.00003). It was not observed in the African, Other, European Non-Finnish, Ashkenazi Jewish, East Asian, and Finnish populations. The p.Glu298Lys residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.